title: Fibrin (ogen)-derived peptide B beta 30-43 is a sensitive marker of activated neutrophils during fibrinolytic-treated acute myocardial infarction in man.
abstract: Neutrophils, elastase, the specifically elastase-derived fibrin split product, B beta 30-43, and C-reactive protein were determined in 30 consecutive patients with acute myocardial infarction. At admission to the coronary care unit 4.2 +/- 0.8 hours after the onset of symptoms, all elements were increased above the reference levels, while compared with convalescent levels, only neutrophils and B beta 30-43 were increased. After the streptokinase treatment, neutrophils, elastase, and B beta 30-43 increased abruptly and peaked (p less than 0.0001) within 1.5 hours. Plasma creatine kinase MB and C-reactive protein reached their peak levels after about 12 and 24 hours, respectively. Peak indices of neutrophils and creatine kinase correlated (r = 0.60, p less than 0.0006). Compared with the age-matched reference range, the convalescent level of B beta 30-43 was increased (p less than 0.0001). Of the tested elements suggestive of neutrophil activation, B beta 30-43 showed signs of being the most sensitive. In keeping with animal studies, neutrophils are activated early during the course of acute myocardial infarction and their activation seems to become accelerated by fibrinolytic treatment. Neutrophils may remain activated in the convalescent phase.
authors.affiliation: Karolinska Institute, Department of Medicine and Clinical Chemistry, Huddinge University Hospital, Sweden.
authors.forename: C
authors.initials: C
authors.lastname: Sylvén
authors.forename: J
authors.initials: J
authors.lastname: Chen
authors.forename: K
authors.initials: K
authors.lastname: Bergström
authors.forename: L
authors.initials: L
authors.lastname: Björkman
authors.forename: R
authors.initials: R
authors.lastname: Wallin
authors.forename: T
authors.initials: T
authors.lastname: Saldeen
mesh_terms: D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis; D003167:Complement Activation; D003402:Creatine Kinase / Q000097:blood; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products; D005345:Fibrinopeptide B; D006801:Humans; D007527:Isoenzymes; D007958:Leukocyte Count; D019272:Leukocyte Elastase; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology*; D010196:Pancreatic Elastase / Q000097:blood; D010446:Peptide Fragments / Q000097:blood*; D013300:Streptokinase / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D015415:Biomarkers; D005338:Fibrin Fibrinogen Degradation Products; D007527:Isoenzymes; D010446:Peptide Fragments; C045012:fibrinogen Bbeta (30-43); D005345:Fibrinopeptide B; D002097:C-Reactive Protein; D003402:Creatine Kinase; D013300:Streptokinase; D010196:Pancreatic Elastase; D019272:Leukocyte Elastase